Friday, May 8, 2020NIH Clinical Trial Testing Antiviral Remdesivir Plus Anti-Inflammatory Drug Baricitinib for COVID-19 BeginsNIAID has initiated a randomized, controlled clinical trial evaluating the safety and efficacy of a treatment regimen of the investigational antiviral remdesivir plus the anti-inflammatory drug baricitinib for COVID-19. The trial is now enrolling hospitalized adults with COVID-19 in the United States. The trial is expected to open at approximately 100 U.S. and international sites and enroll more than 1,000 participants. |
Notice of Funding Opportunities
Hace 17 horas
No hay comentarios:
Publicar un comentario